Navigation Links
Janssen Labs at San Diego Expands to Add Concept Lab and Open Collaboration Space to Accommodate Individual Entrepreneurs and Additional Life Science Start-Ups
Date:2/5/2013

ion center providing emerging companies many of the advantages of being in a big company, without the capital investment. Janssen Labs offers singular bench tops, modular wet lab units and office space on a short-term basis, allowing companies to pay only for the space they need, with an option to quickly expand when they have the resources to do so. Companies residing at Janssen Labs also have access to core research labs hosting specialized capital equipment and shared administrative areas. Janssen Labs' operational support is provided by Prescience International, an external firm that specializes in the set-up and operations of life science innovation centers. Janssen Labs is an open innovation model, and the agreement for space does not grant Janssen any stake in the companies, nor will the companies have a guaranteed future affiliation with Janssen.

Janssen Research & Development, LLC
Janssen Research & Development, LLC (Janssen), is one of the Janssen Pharmaceutical Companies. Janssen is headquartered in Raritan, N.J., and has facilities in Europe, the United States and Asia. Janssen is leveraging drug discovery and drug development in a variety of therapeutic areas, including Neuroscience, Oncology, Immunology, Infectious Diseases, and Cardiovascular and Metabolism to address unmet medical needs worldwide.  

More information can be found at www.janssenlabs.com


'/>"/>
SOURCE Janssen Research & Development, LLC
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Janssen Research & Development Submits XARELTO® (rivaroxaban) to U.S. FDA for the Treatment and Prevention of Recurrent Venous Thromboembolism
2. Janssen Research & Development Submits New Drug Application to U.S. FDA for Canagliflozin to Treat Patients with Type 2 Diabetes
3. Janssen Announces Initiation Of Phase 3 Development Program For Sirukumab In Rheumatoid Arthritis
4. Janssen Biotech Announces Global License and Development Agreement for Investigational Anti-Cancer Agent Daratumumab
5. West Announces Agreement with Janssen Biotech to Develop and Commercialize a New Self-injection Technology
6. Janssen Announces Collaboration with Vertex on Phase 2 Study to Investigate an All-Oral Regimen of Simeprevir (TMC435) and VX-135 for Treatment of Hepatitis C
7. Janssen and Johnson & Johnson to Provide Webcast Presentation of Immunology Pivotal Phase 3 Data Being Presented at the American College of Rheumatology Annual Meeting
8. Efficacy and Safety Data from Phase 2B Trials of Janssens Simeprevir in Hepatitis C Patients with Advanced Fibrosis of the Liver Presented at Annual Meeting of the American Association for the Study of Liver Diseases
9. Janssen Research & Development Announces Establishment of Global Cross-Pharmaceutical Clinical Trial Investigator Databank
10. Janssen Research & Development Submits New Drug Application to U.S. FDA for Canagliflozin/Metformin Fixed-Dose Combination Therapy to Treat Patients with Type 2 Diabetes
11. San Diego Based Neurosurgeon Offers Groundbreaking Treatment to Restore Function for People Suffering from Mobility Inhibiting Paralysis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... /CNW/ - Eisai Limited is pleased to support the Canadian ... book available in Canada . The comic ... educate children and their parents about epilepsy, the most common ... than 300,000 Canadians. Eisai is guided by a corporate philosophy ... the patient is central – there was a need within ...
(Date:8/21/2014)... , Aug. 21, 2014 /PRNewswire-iReach/ -- ... Equipment, Inc. for the third straight year, No. ... 500|5000, an exclusive ranking of the nation,s fastest-growing ... look at the most important segment of the ... Timberland, Dell, Domino,s Pizza, LinkedIn, Zillow, and many ...
(Date:8/21/2014)...  Seventy-one percent of Americans believe the abuse of strong ... health and safety issue in the United States ... by Repass & Partners, a Cincinnati ... severity of the prescription medication abuse problem and the need ... health situation facing our country," Rex Repass , CEO ...
Breaking Medicine Technology:Eisai Pleased to Support Canadian Epilepsy Alliance Comic Book that Teaches Children About Epilepsy 2Carolina's HME Named for Third Straight Year to Inc. Magazine's List of America's Fastest-Growing Private Companies--the Inc. 5000 2Carolina's HME Named for Third Straight Year to Inc. Magazine's List of America's Fastest-Growing Private Companies--the Inc. 5000 3Consumers Desperate For Measures To Curb Prescription Drug Abuse 2Consumers Desperate For Measures To Curb Prescription Drug Abuse 3
... Caremark (NYSE: CVS ) has been named ... by Reputation Institute, in partnership with Forbes Media. The ... RepTrak™ Pulse, a study that measures the 150 largest ... ) Of the companies included in ...
... -- American Oriental Bioengineering, Inc. (NYSE: AOB ) ... (the "NYSE") has notified the Company that it is not ... to timely file its Annual Report on Form 10-K with ... rules, when a Company does not comply with annual report ...
Cached Medicine Technology:CVS Caremark Ranks Among Top 25 Most Reputable Companies in America on Forbes List 2American Oriental Bioengineering Inc. Receives NYSE Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard 2
(Date:8/22/2014)... (PRWEB) August 23, 2014 This ... (Instruments (Workstations, Liquid Handling Systems), Consumables (Tubes), Kits ... Users (Molecular Diagnostics) - Global Forecast to 2018" ... 2013 and is poised to grow at a ... reach $5,672.0 million by 2018. , Browse 98 ...
(Date:8/22/2014)... 2014 With the stage set for ... Store Expo - which will be held in Boston ... op-ed in its online opinion section, Podium. The ... is co-authored by Steven C. Anderson, IOM, CAE, president ... of the MCPHS University School of Pharmacy – Worcester/Manchester. ...
(Date:8/22/2014)... 2014 Millennium Treatment Group has recently noticed ... high level of drug use among teenagers. The treatment facility ... addiction and work to minimize drug abuse. , America is ... drug addiction in history. According to the National Institute ... Americans aged 12 or older—or 9.2 percent of the population—had ...
(Date:8/22/2014)... The regional economy is about to ... on the grow again. The plant will invest ... to boost production of the popular Highlander midsize sport ... investment to $4 billion. This step allows Toyota to ... flexibility to adjust its product mix to meet changing ...
(Date:8/22/2014)... A Penn Medicine team has found that targeted ... urinary tract infections in hospital patients with urinary ... alert was simplified, the rate of improvement dramatically ... their patients need urinary catheters in the first ... need for catheters that have not been removed ...
Breaking Medicine News(10 mins):Health News:Sample Preparation Market by Product and Application Worth $5,672 Million by 2018 - New Research Report by MarketsandMarkets 2Health News:Sample Preparation Market by Product and Application Worth $5,672 Million by 2018 - New Research Report by MarketsandMarkets 3Health News:Sample Preparation Market by Product and Application Worth $5,672 Million by 2018 - New Research Report by MarketsandMarkets 4Health News:The Boston Globe Publishes Value of Pharmacy Op-ed as NACDS Total Store Expo Begins 2Health News:The Boston Globe Publishes Value of Pharmacy Op-ed as NACDS Total Store Expo Begins 3Health News:Millennium Treatment Group Sees Increase in Marijuana Use Among Youth 2Health News:Toyota Indiana Adding 300 Jobs to Build More Highlanders 2Health News:Penn study: Electronic alerts significantly reduce catheter-associated urinary tract infections 2Health News:Penn study: Electronic alerts significantly reduce catheter-associated urinary tract infections 3
... dubious DEA raids on,legal medical marijuana dispensaries, LOS ANGELES, ... federal government needs to reclassify marijuana. People who,need it should ... The Price Is,Right and Power of 10 host Drew Carey ... on drugs., Voters in 12 states have legalized medical ...
... Minn. -- A Mayo Clinic study of a drug that ... demonstrates that the drug may also be effective in treating ... The study, which was done in mouse models, is featured ... , The National Cancer Institute reports that of 240,510 ...
... pregnant, the probability is much greater that her child ... according to a new Nordic study. The investigation ... in collaboration with international colleagues, and is available online ... comprising more than 12,500 children in Sweden, Finland, and ...
... 1 Dynavax Technologies,Corporation (Nasdaq: DVAX ) announced ... will present an overview of the,company at two investor ... Ostrach will present at the CIBC World Markets 18th ... a.m. ET (5:35,a.m. PT). In addition, Ostrach will present ...
... 1 Amira Pharmaceuticals, Inc. announced,completion of the ... discovered oral drug candidate for the treatment of ... announced the start,of a Phase 1 trial for ... the,same inflammatory response. AM103 and AM803 are ...
... plc (LSE: SHP, NASDAQ: SHPGY, TSX: SHQ) the,global specialty biopharmaceutical ... Financial Highlights - Product sales up 41% to $543.1 ... - Net cash provided by operating activities up 51% ... expected to be at least 30% (Q2 guidance: at,least 25%). ...
Cached Medicine News:Health News:Drew Carey Defends Medical Marijuana 2Health News:Mayo Clinic study shows drug could effectively treat, prevent the spread of breast cancer 2Health News:Mayo Clinic study shows drug could effectively treat, prevent the spread of breast cancer 3Health News:Overweight mothers run greater risk of having hyperactive children 2Health News:Dynavax to Present at CIBC World Markets and Acumen BioFin Rodman and Renshaw Healthcare Conferences 2Health News:Amira Pharmaceuticals Announces Favorable Phase 1 Clinical Trial Results for Lead Product Candidate AM103 and Initiates Clinical Studies for the 2nd Entry Molecule for the Treatment of Respiratory and Cardiovascular Disease 2Health News:Amira Pharmaceuticals Announces Favorable Phase 1 Clinical Trial Results for Lead Product Candidate AM103 and Initiates Clinical Studies for the 2nd Entry Molecule for the Treatment of Respiratory and Cardiovascular Disease 3Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 2Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 3Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 4Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 5Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 6Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 7Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 8Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 9Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 10Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 11Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 12Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 13Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 14Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 15Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 16Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 17Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 18Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 19Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 20Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 21Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 22Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 23Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 24Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 25Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 26Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 27Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 28Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 29
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: